{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:25:47Z","timestamp":1790749547721,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"am","delay-in-days":267,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#am"},{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and Aims<\/jats:title>\n            <jats:p>Patients with NAFLD with significant hepatic fibrosis (Stage \u2265 2) are at increased risk of liver\u2010related morbidity and are candidates for pharmacologic therapies. In this study, we compared the diagnostic accuracy of MEFIB (the combination of magnetic resonance elastography [MRE] and Fibrosis\u20104 [FIB\u20104]) and FAST (FibroScan\u2013aspartate aminotransferase; combined liver stiffness measurement by vibration\u2010controlled transient elastography, controlled attenuation parameter, and aspartate aminotransferase) for detecting significant fibrosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Approach and Results<\/jats:title>\n            <jats:p>This prospective cohort study included 234 consecutive patients with NAFLD who underwent liver biopsy, MRE, and FibroScan at the University of California San Diego (UCSD cohort) and an independent cohort (<jats:italic toggle=\"yes\">N<\/jats:italic>\u00a0=\u00a0314) from Yokohama City University, Japan. The primary outcome was diagnostic accuracy for significant fibrosis (Stage \u2265 2). The proportions of significant fibrosis in the UCSD and Yokohama cohorts were 29.5% and 66.2%, respectively. Area under the receiver operating characteristic curve (95% CI) of MEFIB (0.860 [0.81\u20130.91]) was significantly higher than that of FAST (0.757 [0.69\u20130.82]) in the UCSD cohort (<jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.005), with consistent results in the Yokohama cohort (AUROC, 0.899 [MEFIB] versus 0.724 [FAST]; <jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0&lt;\u00a00.001). When used as the rule\u2010in criteria (MEFIB, MRE \u2265 3.3\u00a0kPa and FIB\u20104\u00a0\u2265\u00a01.6; FAST \u2265 0.67), the positive predictive value for significant fibrosis was 91.2%\u201396.0% for MEFIB and 74.2%\u201389.2% for FAST. When used as the rule\u2010out criteria (MEFIB, MRE &lt; 3.3\u00a0kPa and FIB\u20104\u00a0&lt;\u00a01.6; FAST \u2264 0.35), the negative predictive value for significant fibrosis was 85.6%\u201392.8% for MEFIB and 57.8%\u201388.3% for FAST.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>MEFIB has higher diagnostic accuracy than FAST for significant fibrosis in NAFLD, and our results support the utility of a two\u2010step strategy for detecting significant fibrosis in NAFLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.32145","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T16:31:25Z","timestamp":1631118685000},"page":"661-672","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":57,"title":["Magnetic resonance elastography plus Fibrosis\u20104 versus FibroScan\u2013aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH\u2010related fibrosis"],"prefix":"10.1097","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4634-6616","authenticated-orcid":false,"given":"Nobuharu","family":"Tamaki","sequence":"first","affiliation":[{"name":"NAFLD Research Center, Division of Gastroenterology and Hepatology,Department of Medicine,University of California San Diego,La Jolla,California,USA"},{"name":"Department of Gastroenterology and Hepatology,Musashino Red Cross Hospital,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Imajo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Yokohama City University Graduate School of Medicine,Kanagawa,Japan"},{"name":"Department of Gastroenterology,Shin\u2010yurigaoka General Hospital,Kanagawa,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Sharpton","sequence":"additional","affiliation":[{"name":"NAFLD Research Center, Division of Gastroenterology and Hepatology,Department of Medicine,University of California San Diego,La Jolla,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9786-5507","authenticated-orcid":false,"given":"Jinho","family":"Jung","sequence":"additional","affiliation":[{"name":"NAFLD Research Center, Division of Gastroenterology and Hepatology,Department of Medicine,University of California San Diego,La Jolla,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-3534","authenticated-orcid":false,"given":"Nobuyoshi","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Yokohama City University Graduate School of Medicine,Kanagawa,Japan"},{"name":"Department of Gastroenterology,Shin\u2010yurigaoka General Hospital,Kanagawa,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Yokohama City University Graduate School of Medicine,Kanagawa,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Valasek","sequence":"additional","affiliation":[{"name":"Department of Pathology,University of California San Diego,La Jolla,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Behling","sequence":"additional","affiliation":[{"name":"Sharp Medical Group,Department of Pathology,University of California San Diego,La Jolla,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude B.","family":"Sirlin","sequence":"additional","affiliation":[{"name":"Liver Imaging Group,Department of Radiology,University of California San Diego,La Jolla,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Yokohama City University Graduate School of Medicine,Kanagawa,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9991","authenticated-orcid":false,"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[{"name":"NAFLD Research Center, Division of Gastroenterology and Hepatology,Department of Medicine,University of California San Diego,La Jolla,California,USA"},{"name":"Division of Epidemiology,Department of Family Medicine and Public Health,University of California San Diego,La Jolla,California,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"hep32145-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep32145-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep32145-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non\u2010alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta\u2010analysis","volume":"4","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep32145-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/hepr.13535","article-title":"Modelling the economic and clinical burden of non\u2010alcoholic steatohepatitis in east Asia: data from Hong Kong","volume":"50","year":"2020","journal-title":"Hepatol Res"},{"key":"hep32145-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00535-021-01759-2","article-title":"Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database","volume":"56","year":"2021","journal-title":"J Gastroenterol"},{"key":"hep32145-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta\u2010analysis","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep32145-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease\u2010specific mortality in NAFLD after up to 33 years of follow\u2010up","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep32145-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jgh3.12289","article-title":"Discordant pathological diagnosis of non\u2010alcoholic fatty liver disease: a prospective multicenter study","volume":"4","year":"2020","journal-title":"JGH Open"},{"key":"hep32145-bib-0009-20250824","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep32145-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non\u2010invasive assessment of hepatic fibrosis","volume":"69","year":"2020","journal-title":"Gut"},{"key":"hep32145-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nrgastro.2018.10","article-title":"Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD","volume":"15","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep32145-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan\u2010AST (FAST) score for the non\u2010invasive identification of patients with non\u2010alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep32145-bib-0013-20250824","article-title":"MRE combined with FIB\u20104 (MEFIB) index in detection of candidates for pharmacological treatment of NASH\u2010related fibrosis","volume":"70","year":"2021","journal-title":"Gut"},{"key":"hep32145-bib-0014-20250824","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"hep32145-bib-0015-20250824","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"hep32145-bib-0016-20250824","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy\u2010proven nonalcoholic fatty liver disease","volume":"152","year":"2017","journal-title":"Gastroenterology"},{"key":"hep32145-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep32145-bib-0018-20250824","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.cgh.2019.11.060","article-title":"Prospective, same\u2010day, direct comparison of controlled attenuation parameter with the M vs the XL probe in patients with nonalcoholic fatty liver disease, using magnetic resonance imaging\u2010proton density fat fraction as the standard","volume":"18","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32145-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy\u2010to\u2010use software \u201cEZR\u201d for medical statistics","volume":"48","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"47","key":"hep32145-bib-0020-20250824","first-page":"521","article-title":"Advances in ultrasound elastography for nonalcoholic fatty liver disease","volume":"2020","year":"2001","journal-title":"J Med Ultrason"},{"key":"hep32145-bib-0021-20250824","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/hepr.13508","article-title":"Diagnostic accuracy of FibroScan\u2010AST score to identify non\u2010alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non\u2010alcoholic fatty liver disease: comparison between M and XL probes","volume":"50","year":"2020","journal-title":"Hepatol Res"},{"key":"hep32145-bib-0022-20250824","article-title":"Validation of the FibroScan\u2010AST score by vibration\u2010controlled transient and B\u2010mode ultrasound elastography","volume":"20","year":"2021","journal-title":"Hepatol Res"},{"key":"hep32145-bib-0023-20250824","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/liv.14593","article-title":"MR elastography\u2010based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: a multicenter study","volume":"40","year":"2020","journal-title":"Liver Int"},{"key":"hep32145-bib-0024-20250824","first-page":"31374","article-title":"Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD","volume":"30","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32145-bib-0025-20250824","article-title":"Risk difference of liver\u2010related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease","volume":"16","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32145-bib-0026-20250824","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32145-bib-0027-20250824","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"hep32145-bib-0028-20250824","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","article-title":"Novel antisense inhibition of diacylglycerol O\u2010acyltransferase 2 for treatment of non\u2010alcoholic fatty liver disease: a multicentre, double\u2010blind, randomised, placebo\u2010controlled phase 2 trial","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep32145-bib-0029-20250824","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00535-012-0704-y","article-title":"Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels","volume":"48","year":"2013","journal-title":"J Gastroenterol"},{"key":"hep32145-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/hepr.12405","article-title":"Non\u2010alcoholic fatty liver disease fibrosis score and FIB\u20104 scoring system could identify patients at risk of systemic complications","volume":"45","year":"2015","journal-title":"Hepatol Res"},{"key":"hep32145-bib-0031-20250824","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep32145-bib-0032-20250824","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep32145-bib-0033-20250824","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41395-018-0170-0","article-title":"Non\u2010invasive diagnosis of nonalcoholic fatty liver disease","volume":"113","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"hep32145-bib-0034-20250824","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.cgh.2020.04.017","article-title":"Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on united states health care system","volume":"18","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.32145","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.32145","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/am-pdf\/10.1002\/hep.32145","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:03:14Z","timestamp":1756080194000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.32145","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"assertion":[{"value":"2021-06-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}